DEEP LEARNING DOSE PREDICTION MODELS
MACHINE LEARNING FASTER AND SMARTER TREATMENT PLANNING
Generate treatment plans automatically with deep learning driven dose prediction. RaySearch provides your clinic with a roster of machine learning models that have been validated against common radiotherapy treatment protocols. Details about the treatment protocols can be found in the respective model data sheets.
RSL BRAIN PROTON*
Validation patient example
MODEL OVERVIEW
Treatment site Brain
Modality Protons
Treatment technique Validated for pencil beam scanning
Primary prescription [cGy] 5040
Number of fractions 28
Dose per fraction [cGy] 180
* Subject
MODEL PROTOCOL
ROI
Clinical goals
CTV At least 4738 cGy dose at 98.0 % volume
CTV At least 4788 cGy dose at 98.0 % volume
CTV At most 5494 cGy dose at 0.03 cm3 volume
CTV At most 5394 cGy dose at 0.03 cm3 volume
Brain At most 5860 cGy dose at 0.03 cm3 volume
Brainstem core At most 5470 cGy dose at 0.03 cm3 volume
Brainstem surface At most 5860 cGy dose at 0.03 cm3 volume
Optic chiasm At most 5530 cGy dose at 0.03 cm3 volume
Optic nerve L/R At most 5530 cGy dose at 0.03 cm3 volume
Spinal cord At most 3190 cGy dose at 0.03 cm3 volume
Retina L/R At most 4780 cGy dose at 0.03 cm3 volume
Cornea L/R At most 3580 cGy dose at 0.03 cm3 volume
Cochlea L/R At most 3700 cGy average dose
Hippocampus L/R At most 40% volume at 1200 cGy dose
Lacrimal gland L/R At most 3060 cGy average dose
Pituitary At most 2700 cGy average dose
Pituitary At most 4830 cGy average dose
Skin At most 3190 cGy dose at 0.03 cm3 volume
RSL BREAST LEFT*
MODEL OVERVIEW MODEL PROTOCOL
Treatment site Breast
Modality Photons
Treatment technique Validated for SMLC
Primary prescription [cGy] 4005
Number of fractions 15
Dose per fraction [cGy] 267 ROI Clinical goals
PTV-Skin At least 3805 cGy dose at 98.0 % volume
PTV-Skin At least 4005 cGy average dose
PTV-Skin At most 4285 cGy dose at 2.0 % volume
Heart
Heart
Heart
Lung L
Lung L
Lung L
most 1600 cGy dose at 5.0 % volume
most 800 cGy dose at 30.0 % volume
most 320 cGy average dose
most 1600 cGy dose at 15.0 % volume
most 800 cGy dose at 35.0 % volume
most 400 cGy dose at 50.0 % volume
Lung R At most 400 cGy dose at 10.0 % volume
* Subject to regulatory clearance in some markets. Not for marketing in the USA or Canada.
RSL BREAST LEFT 2LVS*
Validation patient example
MODEL OVERVIEW
Treatment site Breast
Modality Photons
Treatment technique Validated for VMAT
Primary prescription [cGy] 4800
Number of fractions 16
Dose per fraction [cGy] 300
* Subject to regulatory clearance in some markets. Not for marketing in the USA or Canada.
MODEL PROTOCOL
ROI Clinical goals
PTV High At least 4560 cGy dose at 98.0 % volume
PTV High At most 4944 cGy dose at 2.0 % volume
PTV High At least 96.0 % volume at 4560 cGy dose
PTV High At most 1.0 % volume at 5040 cGy dose
PTV Low At least 3940 cGy dose at 98.0 % volume
PTV Low-PTV High At most 4800 cGy dose at 1.0 % volume
PTV Low At least 95.0 % volume at 4028 cGy dose
PTV Low-PTV High At most 15.0 % volume at 4452 cGy dose
PTV High At least a conformity index of 0.8 at 4560 cGy isodose
PTV High At least a homogeneity index of 0.9 at 98.0 % volume
PTV Low At least a conformity index of 0.85 at 4028 cGy isodose
PTV Low At least a homogeneity index of 0.8 at 95.0 % volume
Lung L At most 25.0 % volume at 500 cGy dose
Lung L At most 15.0 % volume at 1000 cGy dose
Lung L At most 7.0% volume at 2000 cGy dose
Lung L At most 1.0 % volume at 4000 cGy dose
Lung L At most 600 cGy average dose
Lung R At most 100 cGy average dose
Lung R At most 400 cGy dose at 1.0 % volume
Heart At most 150 cGy average dose
Heart At most 500 cGy dose at 1.0 % volume
Breast R At most 200 cGy average dose
Breast R At most 700 cGy dose at 1.0 % volume
A Coronary L At most 200 cGy dose at 1.0 % volume
Humerus L At most 200 cGy average dose
Brachial Plexus L At most 4240 cGy dose at 0.0 % volume
Liver At most 200 cGy dose at 0.0 % volume
Spinal Canal At most 200 cGy dose at 0.0 % volume
RSL BREAST LOCOREGIONAL 2LVS*
Validation patient example
MODEL OVERVIEW
Treatment site
Breast (or thoracic wall) and nodes
Modality Photons
Treatment technique
Validated for VMAT
Primary prescription [cGy] 6000
Number of fractions 25
Dose per fraction [cGy] 240
MODEL PROTOCOL
Clinical goals varied based on primary target (either breast or thoracic wall) and the involved lymph nodes. Clinical goal values given in the table below represent the ones used for breast with all lymph nodes involved.
ROI
PTV1
PTV1
PTV1
PTV2
PTV2-PTV1
PTV3
PTV3
PTV4
PTV4
PTV5
PTV5
PTV6
PTV6
Organs at risk
* Subject to regulatory clearance in some markets. Not for marketing in the USA or Canada.
Clinical goals
At least 5989 cGy average dose
At least 5700 cGy dose at 99.1 % volume
At most 6180 cGy dose at 0.5 % volume
At least 4750 cGy dose at 98.4 % volume
At most 5250 cGy dose at 9.6 % volume
At least 4750 cGy dose at 99.2 % volume
At most 5250 cGy dose at 0 % volume
At least 4750 cGy dose at 96.0 % volume
At most 5250 cGy dose at 0.1 % volume
At least 4750 cGy dose at 98.0 % volume
At most 5250 cGy dose at 0.1 % volume
At least 4750 cGy dose at 96.2 % volume
At most 5250 cGy dose at 0.6 % volume
Clinical goals varied based on primary target volume and lymph node involvement
RSL OROPHARYNX PROTON 2LVS*
Validation patient example
MODEL PROTOCOL
ROI
CTV High
CTV High
CTV Low
CTV Low
MODEL OVERVIEW
Treatment site Head and neck
Modality Protons
Treatment technique Validated for pencil beam scanning
Primary prescription cGy [RBE] 7000
Number of fractions 35
Dose per fraction cGy [RBE] 200
* Subject to regulatory clearance in some markets. Not for marketing in the USA or Canada.
Clinical goals
At least 6650 cGy dose at 98.0 % volume
At most 7490 cGy dose at 0.0 % volume
At least 5154 cGy dose at 98.0 % volume
At least 5100 cGy dose at 98.0 % volume
CTV High At least 6580 cGy dose at 98.0 % volume
Spinal Cord At most 4500 cGy dose at 0.0 % volume
Brain
Brain
Cochlea L/R
Cochlea L/R
Parotid L/R
At most 5800 cGy dose at 1.0 cm³ volume
At most 6800 cGy dose at 0.0 % volume
At most 4500 cGy dose at 50.0 % volume
At most 5500 cGy dose at 5.0 % volume
At most 2600 cGy dose at 50.0 % volume
Constrictor Muscle I/M/S At most 5500 cGy dose at 50.0 % volume
Brainstem
At most 5400 cGy dose at 0.0 % volume
Submandibular Gland L/R At most 3500.0 cGy dose at 50.0 % volume
Cavity Oral At most 3000 cGy dose at 50.0 % volume
Esophagus S At most 3000 cGy dose at 50.0 % volume
Optic Nerve L/R At most 5400 cGy dose at 0.0 % volume
Eye L/R At most 3000 cGy dose at 0.0 % volume
Lacrimal Gland L/R At most 2500 cGy dose at 50.0 % volume
Glottis At most 4000 cGy dose at 50.0 % volume
Larynx SG At most 4000 cGy dose at 50.0 % volume
Bone Mandible At most 7200 cGy dose at 0.0 % volume
RSL OROPHARYNX 2LVS*
Validation patient example
MODEL OVERVIEW
Treatment site Head and neck
Modality Photons
Treatment technique Validated for VMAT
Primary prescription [cGy] 7000
Number of fractions 35
Dose per fraction [cGy] 200
* Subject to regulatory clearance in some markets. Not for marketing in the USA or Canada.
MODEL PROTOCOL
ROI Clinical goals
PTV High At least 6650 cGy dose at 98.0 % volume
PTV High At most 7490 cGy dose at 1.8 cm³ volume
PTV Low At least 5320 cGy dose at 98.0 % volume
Spinal Cord At most 4500 cGy dose at 0.0 % volume
Brain At most 5800 cGy dose at 1.0 cm³ volume
Brain At most 6800 cGy dose at 0.0 % volume
Cochlea L/R At most 4500 cGy dose at 50.0 % volume
Cochlea L/R At most 5500 cGy dose at 5.0 % volume
Parotid L/R At most 2600 cGy dose at 50.0 % volume
Constrictor Muscle I/M/S At most 5500 cGy dose at 50.0 % volume
Brainstem At most 5400 cGy dose at 0.0 % volume
Submandibular Gland L/R At most 3500 cGy dose at 50.0 % volume
Cavity Oral At most 3000 cGy dose at 50.0 % volume
Esophagus S At most 3000 cGy dose at 50.0 % volume
Optic Nerv L/R At most 5400 cGy dose at 0.0 % volume
Eye L/R At most 3000 cGy dose at 0.0 % volume
Lacrimal Gland L/R At most 2500 cGy dose at 50.0 % volume
Glottis At most 4000 cGy dose at 50.0 % volume
Larynx SG At most 4000 cGy dose at 50.0 % volume
Bone Mandible At most 7200 cGy dose at 0.0 % volume
RSL OROPHARYNX 3LVS*
Validation patient example
MODEL OVERVIEW
Treatment site Head and neck
Modality Photons
Treatment technique Validated for VMAT
Primary prescription [cGy] 6600
Number of fractions 33
Dose per fraction [cGy] 200
* Subject to regulatory clearance in some markets. Not for marketing in the USA or Canada.
MODEL PROTOCOL
PTV High At least 6270 cGy dose at 98.0 % volume
PTV High At most 7062 cGy dose at 1.8 cm³ volume
PTV Mid At least 5700 cGy dose at 98 % volume
PTV Low At least 4750 cGy dose at 98.0 % volume
Spinal Cord At most 4500 cGy dose at 0.0 % volume
Brain At most 5800 cGy dose at 1.0 cm³ volume
Brain At most 6800 cGy dose at 0.0 % volume
Cochlea L/R At most 4500 cGy dose at 50.0 % volume
Cochlea L/R At most 5500 cGy dose at 5.0 % volume
Parotid L/R At most 2600 cGy dose at 50.0 % volume
Constrictor Muscle I/M/S At most 5500 cGy dose at 50.0 % volume
Brainstem At most 5400 cGy dose at 0.0 % volume
Submandibular Gland L/R At most 3500 cGy dose at 50.0 % volume
Cavity Oral At most 3000 cGy dose at 50.0 % volume
Esophagus S At most 3000 cGy dose at 50.0 % volume
Optic Nerv L/R At most 5400 cGy dose at 0.0 % volume
Eye L/R At most 3000 cGy dose at 0.0 % volume
Lacrimal Gland L/R At most 2500 cGy dose at 50.0 % volume
Glottis At most 4000 cGy dose at 50.0 % volume
Larynx SG At most 4000 cGy dose at 50.0 % volume
Bone Mandible At most 7200 cGy dose at 0.0 % volume
RSL LUNG SBRT*
Validation patient example
MODEL OVERVIEW
Treatment site Lung
Modality Photons
Treatment technique Validated for VMAT
Primary prescription [cGy] 4800
Number of fractions 4
Dose per fraction [cGy] 1200
MODEL PROTOCOL
ROI
Clinical goals
PTV At least 99.0 % volume at 4320 cGy dose
PTV At least 95.0 % volume at 4800 cGy dose
PTV At most 8000 cGy dose at 0.0 % volume
Spinal Canal At most 2600 cGy dose at 0.03 cm³ volume
Spinal Canal At most 2080 cGy dose at 0.35 cm³ volume
Spinal Canal At most 1360 cGy dose at 1.2 cm³ volume
Esophagus At most 3000 cGy dose at 0.03 cm³ volume
Esophagus At most 1880 cGy dose at 5.0 cm³ volume
Heart At most 3400 cGy dose at 0.03 cm³ volume
Heart At most 2800 cGy dose at 15.0 cm³ volume
Trachea At most 1560 cGy dose at 4.0 cm³ volume
Trachea At most 3480 cGy dose at 0.03 cm³ volume
Skin At most 3600 cGy dose at 0.03 cm³ volume
Skin At most 3320 cGy dose at 10.0 cm³ volume
Lungs At most 10.0 % volume at 2000 cGy dose
Bronchus At most 3480 cGy dose at 0.03 cm³ volume
Bronchus At most 1560 cGy dose at 4.0 cm³ volume
Brachial Plexus L/R At most 2720 cGy dose at 0.03 cm³ volume
Brachial Plexus L/R At most 2360 cGy dose at 3.0 cm³ volume
* Subject to regulatory clearance in some markets. Not for marketing in the USA or Canada.
RSL PROSTATE*
Validation patient example
MODEL OVERVIEW
Treatment site Prostate
Modality Photons
Treatment technique Validated for VMAT
Primary prescription [cGy] 6000
Number of fractions 20
Dose per fraction [cGy] 300
MODEL PROTOCOL
ROI
CTV
PTV
PTV
Bladder Wall
Bladder Wall
Rectal Wall
Rectal Wall
Femoral Head L/R
Penile Bulb
Penile Bulb
* Subject to regulatory clearance in some markets. Not for marketing in the USA or Canada.
Clinical goals
At least 6000 cGy dose at 99.0 % volume
At least 5700 cGy dose at 99.0 % volume
At most 6300 cGy dose at 1.0 cm³ volume
At most 30.0 % volume at 4600 cGy dose
At most 50.0 % volume at 3700 cGy dose
At most 30.0 % volume at 4600 cGy dose
At most 50.0 % volume at 3700 cGy dose
At most 5.0 % volume at 4300 cGy dose
At most 5000 cGy average dose
At most 150.0 cm³ volume at 5000 cGy dose
RSL PROSTATEBED SVS NODES 2LVS*
MODEL OVERVIEW
Treatment site ProstateBed+SVs+Nodes
Modality Photons
Treatment technique Validated for VMAT
Primary prescription [cGy] 7000
Number of fractions 35
Dose per fraction [cGy] 200
* Subject to regulatory clearance in some markets. Not for marketing in the USA or Canada.
MODEL PROTOCOL
ROI
Validation patient example
Clinical goals
PTV High At least 50.0 % volume at 7700 cGy dose
PTV High At least 98.0 % volume at 6650 cGy dose
PTV High At most 0.03 cm³ volume at 7490 cGy dose
PTV Low At least 50.0 % volume at 5600 cGy dose
PTV Low At least 98.0 % volume at 5320 cGy dose
PTV Low-PTV High At most 0.5 % volume at 5992 cGy dose
Bladder At most 15.0 % volume at 7000 cGy dose
Bladder At most 30.0 % volume at 6500 cGy dose
Bladder At most 60.0 % volume at 4000 cGy dose
Bladder At most 6500 cGy dose at 50.0 % volume
Bladder At most 4000 cGy dose at 70.0 % volume
Small Bowel At most 150.0 cm³ volume at 4500 cGy dose
Femoral Head L/R At most 5.0 % volume at 5000 cGy dose
Rectum At most 15.0 % volume at 7000 cGy dose
Rectum At most 6500 cGy dose at 35.0 % volume
Rectum At most 40.0 % volume at 6000 cGy dose
Rectum At most 55.0% volume at 4000 cGy dose
Rectum At most 80.0 % volume at 3000 cGy dose
Rectum At most 30.0 % volume at 6500 cGy dose
RSL PROSTATE SVS NODES 2LVS*
Validation patient example
* Subject to regulatory clearance in some markets. Not for marketing in the USA or Canada.
MODEL OVERVIEW
Treatment site Prostate, seminal vesicles and nodes
Modality Photons
Treatment technique Validated for VMAT
Primary prescription [cGy] 7700
Number of fractions 35
Dose per fraction [cGy] 220
MODEL PROTOCOL
ROI Clinical goals
PTV High At least 50.0 % volume at 7700.0 cGy dose
PTV High At least 98.0 % volume at 7315.0 cGy dose
PTV Low At least 98.0 % volume at 5320.0 cGy dose
PTV Low At least 50.0 % volume at 5600.0 cGy dose
Bladder At most 15.0 % volume at 7000.0 cGy dose
Bladder At most 15.0 % volume at 7900.0 cGy dose
Bladder At most 25.0 % volume at 7400.0 cGy dose
Bladder At most 30.0 % volume at 6500.0 cGy dose
Bladder At most 35.0 % volume at 6900.0 cGy dose
Bladder At most 50.0 % volume at 6400.0 cGy dose
Bladder At most 60.0 % volume at 4000.0 cGy dose
Rectum At most 3.0 % volume at 7500.0 cGy dose
Rectum At most 15.0 % volume at 7000.0 cGy dose
Rectum At most 15.0 % volume at 7400.0 cGy dose
Rectum At most 25.0 % volume at 6900.0 cGy dose
Rectum At most 30.0 % volume at 6500.0 cGy dose
Rectum At most 35.0 % volume at 6400.0 cGy dose
Rectum At most 40.0 % volume at 6000.0 cGy dose
Rectum At most 50.0 % volume at 5900.0 cGy dose
Rectum At most 55.0 % volume at 5000.0 cGy dose
Rectum At most 65.0 % volume at 4000.0 cGy dose
Rectum At most 80.0 % volume at 3000.0 cGy dose
Small Bowel At most 150.0 cm³ volume at 4500.0 cGy dose
Penile Bulb At most 5100.0 cGy average dose
Femoral Head L/R At most 5.0 % volume at 5000.0 cGy dose
RSL PROSTATE 3LVS*
Validation patient example
MODEL OVERVIEW
Treatment site Prostate
Modality Photons
Treatment technique Validated for VMAT
Primary prescription [cGy] 6000
Number of fractions 20
Dose per fraction [cGy] 300
* Subject to regulatory clearance in some markets. Not for marketing in the USA or Canada.
MODEL PROTOCOL
ROI
Clinical goals
PTV High At least 5700 cGy dose at 99.0 % volume
PTV Mid At least 5470 cGy dose at 99.0 % volume
PTV Low At least 4560 cGy dose at 99.0 % volume
PTV Mid-PTV High At least 5760 cGy dose at 50.0 % volume
PTV Low-PTV Mid At least 4800 cGy dose at 50.0 % volume
PTV Low-PTV Mid At most 5470 cGy dose at 3.0 % volume
PTV Mid At least 99.5 % volume at 5470 cGy dose
PTV Low At least 99.7 % volume at 4560 cGy dose
Bladder At most 4079 cGy dose at 50.0 % volume
Bladder At most 4860 cGy dose at 25.0 % volume
Bladder At most 6000 cGy dose at 5.0 % volume
Rectum At most 2460 cGy dose at 80.0 % volume
Rectum At most 3240 cGy dose at 70.0 % volume
Rectum At most 4079 cGy dose at 60.0 % volume
Rectum At most 4860 cGy dose at 50.0 % volume
Rectum At most 5280 cGy dose at 30.0 % volume
Rectum At most 5700 cGy dose at 15.0 % volume
Rectum At most 6000 cGy dose at 3.0 % volume
Femoral Head L/R At most 4080 cGy dose at 50.0 % volume
Rectum At most 2420 cGy dose at 60.0 % volume
Rectum At most 2890 cGy dose at 50.0 % volume
Rectum At most 4029 cGy dose at 30.0 % volume
Rectum At most 2070 cGy dose at 70.0 % volume
Penile Bulb At most 4080 cGy dose at 50.0 % volume
Penile Bulb At most 4860 cGy dose at 10.0 % volume
Bowel Space At most 4080 cGy dose at 17.0 cm³ volume
RSL RECTUM*
Treatment site Rectum
Modality Photons
Treatment technique Validated for VMAT
Primary prescription [cGy] 5000
Number of fractions 20
Dose per fraction [cGy] 250
ROI
Clinical goals
PTV At least 4750 cGy dose at 98.0 % volume
PTV At most 5450 cGy dose at 1.0 % volume
PTV At least 98.0 % volume at 4750 cGy dose
PTV At most 1.0 % volume at 5350 cGy dose
Bladder At most 0.1 cm³ volume at 5150 cGy dose
Bladder At most 35.0 % volume at 4500 cGy dose
Bowel Space At most 120.0 cm³ volume at 3000 cGy dose
Bowel Space At most 500.0 cm³ volume at 1500 cGy dose
Femoral Head L/R At most 0.1 cm³ volume at 5000 cGy dose
Femoral Head L/R At most 30.0 % volume at 4000 cGy dose
* Subject to regulatory clearance in some markets. Not for marketing in the USA or Canada.
ADVANCING CANCER TREATMENT
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch® markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand®**, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems.
RaySearch software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.
*Subject to regulatory clearance in some markets. **RayCommand is not available for use or sale in the USA or Canada.